Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Chronic Spontaneous Urticaria (LIBERTY-CSU CUPID)
NCT04180488Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of dupilumab in chronic spontaneous urticaria (CSU), sponsored by Sanofi. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04180488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180488.